scholarly journals Conventional, diffusion, and dynamic contrast-enhanced MRI findings for differentiating metaplastic Warthin’s tumor of the parotid gland

2021 ◽  
Vol 104 (2) ◽  
pp. 003685042110185
Author(s):  
Chuan-Hai Jia ◽  
Sheng-Yu Wang ◽  
Qin Li ◽  
Jia-Ming Qiu ◽  
Xin-Ping Kuai
Keyword(s):  
Parotid Gland ◽  
Warthin’S Tumor ◽  
Dce Mri ◽  
Conventional Mri ◽  
Contrast Enhanced ◽  
Significant Difference ◽  
Marked Enhancement ◽  
Warthin's Tumor ◽  
Mri Characteristics ◽  
Tumor Types

The purpose of this study was to explore conventional, diffusion, and dynamic contrast-enhanced MRI (DCE-MRI) characteristics for differentiating metaplastic Warthin’s tumor (MWT) from other tumor types of the parotid gland, including non-metaplastic Warthin’s tumor (non-MWT), pleomorphic adenoma (PA), and malignant tumor (MT). A total of 178 patients with histologically proven tumors of the parotid gland, including 21 MWTs, 49 non-MWTs, 66 PAs, and 42 MTs, were enrolled in the study. Conventional MRI was performed in all patients. One hundred and fifty patients had preoperative diffusion-weighted MR imaging (DWI), and 62 patients had preoperative DCE-MRI. The differences in the conventional, DCE-MRI, and DWI records between MWTs and the other three tumor types were statistically evaluated. Compared with non-MWTs and PAs, there was a statistically significant difference in circumscription ( p < 0.01). The ill-defined circumscription was more common in MWTs than non-MWTs and PAs. Compared with PAs, there was a statistically significant difference in morphology ( p < 0.05). The lobulated morphology was more common in PAs than MWTs. Compared with PAs and MTs, there was a statistically significant difference in the T2 signal of the solid component ( p < 0.01). The T2 moderate intensity of solid components was more common in MWTs than PAs and MTs. The solid components of PAs mostly showed hyperintense on T2-weighted imaging. Cyst/necrosis was more common in MWTs than PAs and MTs. Hyperintense of cyst/necrosis was more common in MWTs and non-MWTs. With respect to contrast enhancement, 52.4% MWTs exhibited moderate or marked enhancement, and most non-MWTs (81.6%) exhibited mild enhancement. Most PAs (84.8%) exhibited marked enhancement. The mean ADC value of MWTs (0.94 × 10−3 ± 0.11 mm2/s) was significantly lower than that of the PAs (1.60 × 10−3 ± 0.17 mm2/s) ( p < 0.001). On DCE-MRI, six of eight MWTs demonstrated TIC of type B. Although MWT is rare, conventional MRI characteristics, DWI and DCE-MRI can provide useful information for differentiating MWT from other parotid mass.

scholarly journals RETRACTED ARTICLE: The diagnostic value of combined dynamic contrast-enhanced MRI (DCE-MRI) and diffusion-weighted imaging (DWI) in characterization of parotid gland tumors

2020 ◽  
Vol 51 (1) ◽  
Author(s):  
Mohamed Ali EL-Adalany ◽  
Amany Ezzat Mohamed Mousa ◽  
Dina EL-Metwally
Keyword(s):  
Parotid Gland ◽  
Diagnostic Value ◽  
Adc Value ◽  
Dce Mri ◽  
Parotid Gland Tumors ◽  
Contrast Enhanced ◽  
Combined Use ◽  
Significant Difference ◽  
And Diffusion

Abstract Background MRI is considered to be the imaging modality of choice in preoperative diagnosis of parotid gland tumors and differentiating benign from malignant ones. Recently, functional MR imaging sequences including dynamic contrast-enhanced magnetic resonance imaging (DCE- MRI) and diffusion-weighted imaging (DWI) have significantly contributed to the diagnosis of head and neck masses. The purpose of this study was to evaluate the diagnostic value of combined DCE-MRI and DWI in characterization of parotid gland tumors. Results There was significant difference between benign and malignant parotid gland tumors as regard the type of time intensity curve (TIC) (P < 0.001). There was significant difference between pleomorphic adenoma (PMA) and malignant parotid gland tumors (MT) as regard mean ADC value (P = 0.046) and TTP (P = 0.002). There was no significant difference between Warthin’s tumor (WT) and malignant parotid gland tumors as regard the ADC value and TTP (P > 0.5); on the other hand, WT usually have high WR when compared with MT (P = 0.004). Combined use of DCE-MRI and DWI had 100% sensitivity, 90.5% specificity, and 93.3% accuracy in differentiating benign from malignant parotid gland tumors. Conclusion Combined use of DCE-MRI and DWI could result in high sensitivity, specificity, and diagnostic accuracy in characterization of parotid gland tumors.

Mucoepidermoid carcinoma arising in Warthin's tumor of the parotid gland

2002 ◽  
Vol 52 (10) ◽  
pp. 653-656 ◽  
Author(s):  
Shin-ichi Yamada ◽  
Takemitsu Matsuo ◽  
Shuichi Fujita ◽  
Kazutaka Suyama ◽  
Akira Yamaguchi ◽  
...  
Keyword(s):  
Parotid Gland ◽  
Mucoepidermoid Carcinoma ◽  
Warthin’S Tumor ◽  
Warthin's Tumor

Characteristic sonographic findings of Warthin's tumor in the parotid gland

2004 ◽  
Vol 32 (2) ◽  
pp. 78-81 ◽  
Author(s):  
Jinna Kim ◽  
Eun-Kyung Kim ◽  
Cheong Soo Park ◽  
Yoon-Seok Choi ◽  
Young Ho Kim ◽  
...  
Keyword(s):  
Parotid Gland ◽  
Warthin’S Tumor ◽  
Warthin's Tumor

Surgical treatment of benign parotid gland tumors in the years 2014–2018 at the ENT department of Hospital České Budějovice, a.s.

2021 ◽  
Vol 70 (2) ◽  
pp. 82-88
Author(s):  
Hana Zapletalová ◽  
Martin Kuchař ◽  
Lubor Mrzena
Keyword(s):  
Surgical Treatment ◽  
Parotid Gland ◽  
Facial Nerve ◽  
Pleomorphic Adenoma ◽  
Benign Tumors ◽  
Histological Structure ◽  
Warthin’S Tumor ◽  
Parotid Gland Tumors ◽  
Warthin's Tumor ◽  
Keywords Parotid Gland

ntroduction: Salivary tumors represent a heterogeneous group of tumors of diverse location, histological structure and bio logical behavior. The purpose of this study was a retrospective evaluation of surgical treatment of a group of patients with newly dia gnosed benign tumors of the parotid salivary gland operated in the years 2014–2018 at the ENT department of Hospital České Budějovice, a.s. Material and methods: A type of surgery, defi nitive histology, postoperative complications and a number of recurrences were monitored. The data were evaluated by descriptive statistical methods. Results: A total of 190 surgeries with benign histological fi ndings in 182 patients were performed. The most common benign result was Warthin‘s tumor (90 cases, 47.4%), followed by pleomorphic adenoma (66 cases, 34.7%). Uncommon histological types of tumors were dia gnosed in 14 patients (7.4%). Non-tumorous fi ndings were found in 20 cases (10.5%). The most frequently performed procedure in 84 cases (44.2%) was extracapsular extirpation. Transient lesion in the area of innervation of the temporofacial and / or cervicofacial branch of the facial nerve was present in 34 (17.9%) patients. Permanent paresis of some of the branches of the facial nerve was reported in 2 (1.1%) patients. In 12 patients, the postoperative course was complicated by the development of salivary fi stula (6.3%). Pleomorphic adenoma relapsed after extracapsular extirpation in 5 cases (20.0%). After partial parotidectomy, one recurrence of pleomorphic adenoma (3.6%) was recorded. Warthin‘s tumor relapsed after simple extirpation in 4 cases (20.0%). Conclusion: Our evaluation results of the surgical treatment of benign parotid gland tumors lead us to make further eff orts improve the care of our patients. We see reserves mainly in the routine use of ultrasonographic examination with performance FNAC and thus planning a safe and suffi ciently radical operational solution. Keywords: parotid gland – pleomorphic adenoma – Warthin‘s tumor – parotidectomy – recurrence – facial nerve paresis – FNAC

scholarly journals Warthin's tumor with necrotizing tuberculous granulomatous inflammation causing severe facial nerve adhesion in parotid gland

Medicine ◽  
2020 ◽  
Vol 99 (7) ◽  
pp. e18763
Author(s):  
Shih-Lung Chen ◽  
Cheng-Cheng Hwang ◽  
Yu-Chih Liu ◽  
Wei-Ting Chen ◽  
Shih-Wei Yang
Keyword(s):  
Parotid Gland ◽  
Facial Nerve ◽  
Granulomatous Inflammation ◽  
Warthin’S Tumor ◽  
Warthin's Tumor

scholarly journals A Case of Synchronous Pleomorphic Adenoma and Warthin’s Tumor in the Ipsilateral Parotid Gland

2014 ◽  
Vol 140 (0) ◽  
pp. 104-105
Author(s):  
Koichiro Yamada ◽  
Yohei Kumabe ◽  
Shinzo Tanaka ◽  
Yasuyuki Hiratsuka ◽  
Yoshiki Watanabe ◽  
...  
Keyword(s):  
Parotid Gland ◽  
Pleomorphic Adenoma ◽  
Warthin’S Tumor ◽  
Warthin's Tumor

scholarly journals A case of salivary duct carcinoma in Warthin's tumor of the parotid gland

2015 ◽  
Vol 25 (2) ◽  
pp. 227-233 ◽  
Author(s):  
Yasuhito Mihashi ◽  
Takayuki Sueta ◽  
Yoshikazu Sugiyama ◽  
Tsutomu Fukuzaki ◽  
Satoshi Nimura ◽  
...  
Keyword(s):  
Parotid Gland ◽  
Salivary Duct Carcinoma ◽  
Warthin’S Tumor ◽  
Salivary Duct ◽  
Duct Carcinoma ◽  
Warthin's Tumor

Phase I study of BAY 57–9352, a VEGFR-2 inhibitor, in cycles of 14 days on/7 days off in patients with advanced solid tumors

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 3089-3089
Author(s):  
D. Strumberg ◽  
K. Mross ◽  
M. Scheulen ◽  
A. Frost ◽  
S. Hedbom ◽  
...  
Keyword(s):  
Dose Reduction ◽  
Tyrosine Kinases ◽  
Dependent Manner ◽  
Dce Mri ◽  
Plasma Biomarkers ◽  
Contrast Enhanced ◽  
Grade 3 ◽  
Favorable Safety ◽  
Tumor Types ◽  
Anti Tumor Activity

3089 Background: BAY 57–9352 (BAY) inhibits the VEGFR-2 and VEGFR-3 tyrosine kinases, in addition to PDGFR-β and c-kit. BAY showed anti-tumor activity in colon, breast, pancreatic, and NSCLC preclinical models. Methods: This study investigated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of oral BAY in 14 days on/7 days off treatment cycles until discontinuation due to toxicity or progression. PK was assessed on days 1 and 14 of cycle 1. Dynamic contrast-enhanced MRI (DCE-MRI) was performed at baseline and in cycles 1–3. Plasma biomarkers (VEGF, sVEGFR-2) were assessed at each cycle. Results: 77 patients (pts) were enrolled at doses from 20 mg once daily to 1500 mg twice daily (bid). Common tumor types were CRC (31%) and RCC (16%). Frequent drug-related adverse events (≥5% pts) were hypertension (all grades, 11 pts [14%]; grade 3, 10 [13%]), hoarseness (10 [13%], only grade 1/2), anorexia (7 [9%], only grade 1/2), myalgia (6 [8%], only grade 1/2), fatigue (5 [6%], only grade 1/2), and diarrhea (all grades, 4 [5%]; grade 3, 1 [1%]). Hypertension in cycle 1 caused a dose reduction/interruption in 3 pts. One pt had diarrhea in cycle 7 requiring a dose reduction. One pt discontinued due to fatigue in cycle 8. BAY AUC increased dose-proportionally up to 900 mg bid. As measured by DCE-MRI, pts with CRC showed the greatest decrease in iAUC60 of Gd-DTPA, a parameter related to tumor blood flow and permeability. One pt with RCC achieved a partial response (PR); another had significant tumor shrinkage not reaching formal criteria (RECIST) for PR. PD responses (VEGF and sVEGFR-2 levels) increased in a dose-dependent manner up to 900 mg bid. Conclusions: The MTD was not reached for BAY up to 1500 mg bid in a 14 days on/7 days off schedule. BAY had a favorable safety profile. Tumor efficacy was shown in individual patients. The PD effect of BAY was demonstrated by DCE-MRI and plasma biomarkers. The recommended dose for Phase II evaluations is 900 mg bid. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document